Quote:
Originally Posted by zanpar321
Has anyone seen any news of a Phase 2 study using Nilotinib?
“To my knowledge, this study represents the first time a therapy appears to reverse — to a greater or lesser degree depending on stage of disease — cognitive and motor decline in patients with these neurodegenerative disorders,” says Pagan. “But it is critical to conduct larger and more comprehensive studies before determining the drug’s true impact.”
http://www.themarketbusiness.com/201...eimers-disease |
The researchers are hoping to begin a new trial in 2016. Novartis has committed to supplying the drugs, but the team has not yet secured the additional funding required. The last I heard was they are looking for $3 million and have secured commitments for about $1 million so far. I also heard that they have been turned down by some common funding sources because they have not actually published their previous findings or reported actual data from the study. Other than what we have seen in the media reports, there has been no professional data release. We do need to keep in mind that this was just a small, open-label, study. I have no idea why the trial team hasn't followed normal protocols in data dissemination. I know several funding sources who have backed away because of this even though the science seems to make sense and the reports they released were intriguing.